4.7 Article

Quantitative proteomic profiling of primary cancer-associated fibroblasts in oesophageal adenocarcinoma

期刊

BRITISH JOURNAL OF CANCER
卷 118, 期 9, 页码 1200-1207

出版社

SPRINGERNATURE
DOI: 10.1038/s41416-018-0042-9

关键词

-

类别

资金

  1. Wessex Cancer Trust
  2. CRUK-Southampton Internal Pilot Grant
  3. EU-FP7 Marie Curie (CANOMICS)
  4. Annual Adventures in Research-University of Southampton
  5. EU-Excellence II-Systems Biology Framework FRA-SYS [4072]
  6. Cancer Research UK [C34999/A13719, RG84119]
  7. MRC Clinician Scientist Fellowship [G1002565]

向作者/读者索取更多资源

BACKGROUND: Cancer-associated fibroblasts (CAFs) form the major stromal component of the tumour microenvironment (TME). The present study aimed to examine the proteomic profiles of CAFs vs. normal fibroblasts (NOFs) from patients with oesophageal adenocarcinoma to gain insight into their pro-oncogenic phenotype. METHODS: CAFs/NOFs from four patients were sub-cultured and analysed using quantitative proteomics. Differentially expressed proteins (DEPs) were subjected to bioinformatics and compared with published proteomics and transcriptomics datasets. RESULTS: Principal component analysis of all profiled proteins showed that CAFs had high heterogeneity and clustered separately from NOFs. Bioinformatics interrogation of the DEPs demonstrated inhibition of adhesion of epithelial cells, adhesion of connective tissue cells and cell death of fibroblast cell lines in CAFs vs. NOFs (p < 0.0001). KEGG pathway analysis showed a significant enrichment of the insulin-signalling pathway (p = 0.03). Gene ontology terms related with myofibroblast phenotype, metabolism, cell adhesion/migration, hypoxia/oxidative stress, angiogenesis, immune/inflammatory response were enriched in CAFs vs. NOFs. Nestin, a stem-cell marker up-regulated in CAFs vs. NOFs, was confirmed to be expressed in the TME with immunohistochemistry. CONCLUSIONS: The identified pathways and participating proteins may provide novel insight on the tumour-promoting properties of CAFs and unravel novel adjuvant therapeutic targets in the TME.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据